Literature DB >> 20637335

Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.

Insoo Suh1, Menno R Vriens, Marlon A Guerrero, Ann Griffin, Wen T Shen, Quan-Yang Duh, Orlo H Clark, Electron Kebebew.   

Abstract

BACKGROUND: Serum thyroglobulin (Tg) is the most accurate biomarker for thyroid cancer recurrence. However, some clinicians measure preoperative Tg as a diagnostic cancer marker despite lack of supporting evidence. We examined whether Tg accurately predicts malignancy in follicular or Hürthle-cell neoplasms.
METHODS: We reviewed 366 patients who underwent thyroidectomies for follicular/Hürthle-cell neoplasms. We compared Tg in malignant versus benign tumors by univariate and receiver-operator characteristic analyses. We also examined several Tg-derived indices that normalized Tg to known confounding factors including nodule size, thyroid function, and type of Tg assay.
RESULTS: Thirty-nine patients met inclusion criteria for analysis. There were no differences between malignant (n = 16) and benign (n = 23) lesions in Tg or any of the normalized indexes. Receiver-operator characteristic analysis revealed an area under the curve of .59. Lesions with Tg levels greater than 500 mug/L had a positive predictive value of .75.
CONCLUSIONS: Tg has poor accuracy for predicting malignancy in follicular or Hürthle-cell thyroid neoplasms. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637335     DOI: 10.1016/j.amjsurg.2009.08.030

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  14 in total

Review 1.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

2.  Markedly elevated thyroglobulin levels in the preoperative thyroidectomy patient correlates with metastatic burden.

Authors:  Sarah C Oltmann; Glen Leverson; Suzy Hsiu-I Lin; David F Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2013-12-18       Impact factor: 2.192

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs.

Authors:  Mio Kitano; Reza Rahbari; Erin E Patterson; Yin Xiong; Nijaguna B Prasad; Yongchun Wang; Martha A Zeiger; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2011-05-07       Impact factor: 5.344

5.  Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy.

Authors:  Teng Zhao; Jun Liang; Tianjun Li; Wen Gao; Yansong Lin
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

7.  Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.

Authors:  Syed Zubair Hussain; Maseeh Uz Zaman; Sarwar Malik; Nanik Ram; Ali Asghar; Unaib Rabbani; Nida Aftab; Najmul Islam
Journal:  J Thyroid Res       Date:  2014-04-09

8.  Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules.

Authors:  Eun Kyung Lee; Ki-Wook Chung; Hye Sook Min; Tae Sung Kim; Tae Hyun Kim; Jun Sun Ryu; Yoo Seok Jung; Seok Ki Kim; You Jin Lee
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

9.  Incidental thyroid carcinoma diagnosed after total thyroidectomy for benign thyroid diseases: incidence and association with thyroid disease type and laboratory markers.

Authors:  D Askitis; E I Efremidou; M Karanikas; A Mitrakas; G Tripsianis; A Polychronidis; N Liratzopoulos
Journal:  Int J Endocrinol       Date:  2013-11-20       Impact factor: 3.257

10.  Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland.

Authors:  Rok Petric; Hana Besic; Nikola Besic
Journal:  World J Surg Oncol       Date:  2014-09-12       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.